AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01513486 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: immobilization
Study NCT03994432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model.
Study NCT00312663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falciparum Malaria Protein 11 with AS01B adjuvant.
Description: malaria experimental vaccine
Study NCT02914028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block
Description: A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
Study NCT02914028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol and paracetamol
Description: Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
Study NCT00708084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL184
Description: CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study NCT00708084 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG
Description: HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study NCT00935090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Study NCT02945891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens
Description: Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
Study NCT03408119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Dried plum fruit, 100g or 50g depending on treatment group randomized to
Study NCT03408119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D and 450mg elemental calcium
Description: Supplemental vitamin D and calcium to protect against further bone loss
Study NCT02536404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Study NCT02536404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03137667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-located Influenza Vaccination
Description: Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
Study NCT03408119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 800 IU vitamin D and 450mg elemental calcium
Description: Supplemental vitamin D and calcium to protect against further bone loss
Study NCT02433431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training
Description: Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
Study NCT02433431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Attention Only Training
Description: Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
Study NCT02433431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Analytic Thinking Training
Description: Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
Study NCT03030742 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids
Study NCT02278523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle
Study NCT02278523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle
Study NCT04821362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound group
Description: In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
Study NCT04821362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Device Group
Description: In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
Study NCT00289055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Cordis SMART™ Nitinol Stent
Study NCT00289055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: balloon angioplasty
Study NCT01629199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEGF(recombinant human Epidermal Growth Factor)
Study NCT02616913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R,R-monatin
Description: Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
Study NCT01564511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait trainer treatment
Description: Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
Study NCT02616913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
Study NCT01564511 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 5 mg QD tablet
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 15 mg QD tablet
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 50 mg QD tablet
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 100 mg QD tablet
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 200 mg QD
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator matching INCB013739
Description: Orally once daily tablet
Study NCT00698230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01638377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
Study NCT01638377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
Study NCT02616913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject consumes placebo in one of 3 treatment periods
Study NCT02491385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural analgesia
Description: In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
Study NCT02491385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv-PCA
Description: iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
Study NCT02492945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ml-Rejuvinex
Description: They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
Study NCT02492945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3ml-15%-dextrose solution
Description: They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
Study NCT01247857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 30 mg
Description: Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
Study NCT01247857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 30 mg
Description: intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
Study NCT01247857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
Study NCT02868203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT after stent implantation
Study NCT02868203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eLuting stent
Study NCT01488253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
Study NCT01488253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
Study NCT01902940 — intervention group
Intervention type: OTHER
Intervention: Natural History
Description: Assessment of natural history in IBM and CCFDN
Study NCT02824484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GWDP
Description: In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness.
Study NCT02824484 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
Study NCT03002974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: 100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
Study NCT03002974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40 mg
Description: 1 mL intramuscular injection of a 40 mg/mL injectable suspension
Study NCT03002974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Anakinra 100 mg
Description: sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
Study NCT03002974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Anakinra 100 mg
Description: sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
Study NCT03002974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Triamcinolone Acetonide 40 mg
Description: 1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
Study NCT01580930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 12 weeks, 5 days of week, 40 min per session of exercise training
Study NCT01580930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sedentary time reduction
Description: participants provided with strategies to decrease sitting
Study NCT01580930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercsie training plus sedentary time reduction
Description: 12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
Study NCT01629199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of rhEGF(recombinant human Epidermal Growth Factor)
Study NCT00610363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
Study NCT00610363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rilonacept)
Description: Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
Study NCT01055899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN88
Description: Single SC Dose
Study NCT02288884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acticoat PostOp
Study NCT02907476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Study NCT02907476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Study NCT02929654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio®
Description: Colour Enhanced Blood Glucose Meter.
Study NCT02288884 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OpSite PostOp
Study NCT01814787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA Type 2 Diabetes Module
Description: Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI > 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
Study NCT02929654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio® Flex
Description: Colour Enhanced Blood Glucose Meter.
Study NCT03251885 — intervention group
Intervention type: OTHER
Intervention: swabs
Description: Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
Study NCT03499847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardised face-to-face counselling session
Description: the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
Study NCT03499847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: advanced medical directive pamphlet
Description: A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
Study NCT02929654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subject's Own Blood Glucose Meter
Description: Subject's Own Blood Glucose Meter
Study NCT03156647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Level of alpha-synuclein
Description: Test of levels of total and ratio total:oligomeric in saliva
Study NCT01229462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: brimonidine tartrate/timolol fixed combination ophthalmic solution
Description: One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study NCT01229462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate ophthalmic solution
Description: One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study NCT01229462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol ophthalmic solution
Description: One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study NCT01229462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fixed combination vehicle
Description: Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Study NCT03134079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apple crisp
Description: Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
Study NCT03134079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apple crisp
Description: Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.